Kailos Genetics

Executive Summary

Kailos Genetics is a US-based biotechnology company enabling precision medicine through its proprietary TargetRich™ enrichment technology and next-generation sequencing. Operating a CAP-accredited, CLIA-certified clinical laboratory alongside a reagent supply business, the company provides hereditary cancer risk and pharmacogenomic testing. Founded in 2014 and headquartered in Huntsville, Alabama, Kailos aims to democratize access to advanced genetic diagnostics. Despite its niche focus, the company faces competition from larger players like Invitae and Myriad Genetics. Its private status and limited public financial data restrict visibility, but its dual revenue model (clinical services and reagent sales) offers diversification. Near-term growth hinges on expanding test menus, securing pharmaceutical partnerships for companion diagnostics, and obtaining FDA clearances for key assays.

Upcoming Catalysts (preview)

• Q3 2026Launch of Expanded Hereditary Cancer Panel70% success
• Q1 2027Strategic Partnership for Pharmacogenomic Testing50% success
• Q4 2026Publication of Clinical Validation Study80% success